Kelly L. Close

TL;DR: Biosimilar insulins have the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes, but they will have to overcome numerous regulatory hurdles, meet a variety of commercial demands, and effectively confront competition from both established and next-generation branded insulin products before they can succeed on the global market.

TL;DR: The characteristics of an ideal diabetes therapy are described from the perspective of patients, physicians, payors, and financial analysts and how well currently available therapies and several late-stage candidates meet these guideposts are examined.

TL;DR: This review offers key background information on the current state of digital health in diabetes, six of the most promising digital health technologies and services, and the challenges that remain.

TL;DR: Overall, the dQ&A survey indicates that the majority of patients are willing to consider biosimilar insulins, but manufacturers will need to work proactively to address and assuage patient concerns regarding efficacy, safety, drug administration, and other factors.

TL;DR: In this paper , the authors provide recommendations on how to optimise continuous glucose monitoring (CGM) derived glucose data collection in clinical studies, including specific glucose metrics and specific metrics that should be evaluated.